99PLikelihood of targeted therapy recommendations for advanced solid tumours. (7th November 2019)

• Record Type: Journal Article
• Authors: Taghizadeh, H; Prager, G; Müllauer, L; Mader, R M
• Is Part Of: Annals of oncology. Volume 30(2019)Supplement 7
• Publication Date: 2019-11-07
• Subjects: Oncology -- Periodicals; 616.992
• DOI: 10.1093/annonc/mdz413.103
• Languages: English
• ISSNs: 0923-7534

Abstract

Abstract: Background: Advanced therapy-refractory cancer diseases have a poor prognosis and constitute a major challenge for adequate treatment strategies. In this analysis, we aimed to show the potential and the likelihood of targeted therapy recommendations in patients with different types of advanced solid tumors for whom no standard treatment was available. Methods: In this single center, real-world retrospective analysis of our precision medicine platform, we describe the likelihood of targeted therapy recommendations for 519 patients diagnosed with 19 different types of advanced solid tumors with at least 10 patients per tumor type. Tumor samples of the patients were examined using next-generation sequencing panel, immunohistochemistry, fluorescence in situ hybridization, and RNA fusion panel. Results: In total, we identified 1200 molecular aberrations in 519 patients. The 10 predominant mutations were TP53 (n = 238), KRAS (n = 108), PIK3CA (n = 57), PTEN (n = 35), APC (n = 32), ATM (n = 30), CDKN2A (n = 29), NOTCH1 (n = 27), SMAD4 (n = 21), and PIK3R1 (n = 18) that accounted for nearly half of the molecular alterations (49.6%). For 55% of all patients a molecular driven targeted therapy approach was offered. In over half of the cases of 14 different solid tumor types a targeted therapy was recommended. The five highest rates for therapy suggestion were observed in thyroid cancer (92%), lung cancer (76%), hepatocellular carcinoma (72%), neuroendocrine tumors (65%), and primary brain tumors (64%). The lowest rates were seen in pancreatic ductal adenocarcinoma (38%), lymphoma (33%), and sarcoma (31%). Conclusions: Our platform for precision medicine provided meaningful molecular-driven therapy recommendations for most patients with advanced therapy refractory solid tumors for whom no standard therapy regimen was available. Legal entity responsible for the study: Medical University of Vienna. Funding: Has not received any funding. Disclosure: H. Taghizadeh: Travel / Accommodation / Expenses: Roche. All other authors have declared no conflicts of interest.